Compare BTOC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BTOC | ANL |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 52.0M |
| IPO Year | 2024 | 2023 |
| Metric | BTOC | ANL |
|---|---|---|
| Price | $0.61 | $1.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 10.6K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $197,399,541.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.35 | N/A |
| 52 Week Low | $0.41 | $1.10 |
| 52 Week High | $6.18 | $2.99 |
| Indicator | BTOC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 45.42 |
| Support Level | $0.45 | $1.32 |
| Resistance Level | $0.62 | $1.59 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 85.46 | 44.83 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.